Drug Profile
Research programme: cancer and inflammatory disease antibody therapeutics - Dyax/Zenyth
Latest Information Update: 19 Apr 2010
Price :
$50
*
At a glance
- Originator Dyax; Zenyth Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 22 Feb 2006 Preclinical trials in Cancer in Australia (unspecified route)
- 22 Feb 2006 Preclinical trials in Cancer in USA (unspecified route)
- 22 Feb 2006 Preclinical trials in Inflammation in Australia (unspecified route)